- Endo Health Solutions (ENDP -5.9%) shares sink on widening Q4 losses after the drug maker warned of a significant writedown and high litigation expenses earlier this month.
- Revenue plunged 27% Y/Y, and the company issued a weak FY 2014 outlook, seeing EPS of $3.40-$3.65 vs. $3.93 analyst consensus estimate, and revenues of $2.50B-$2.62B vs. $2.56B consensus.
- Lidoderm sales plummeted 87% to $36.4M while Opana ER sales dropped 14% to $53.7M: ENDP agreed to pay $193M earlier this month to settle allegations that it marketed Lidoderm for uses not approved by regulatory authorities.
Endo International plc (ENDP): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report
at Zacks.com (Nov 7, 2014)